Publications by Erik Fink Eriksen
109 publications found
Original articles
Reconstruction of Remodeling units reveals positive effects after 2 and 12 months of Romosozumab treatment
J Bone Miner Res (in press)
DOI 10.1093/jbmr/zjae055, PubMed 38640512
Validation of forearm fracture diagnoses in administrative patient registers
Arch Osteoporos, 18 (1), 111
DOI 10.1007/s11657-023-01322-x, PubMed 37615791
Reference Intervals for Bone Impact Microindentation in Healthy Adults: A Multi-Centre International Study
Calcif Tissue Int, 112 (3), 338-349
DOI 10.1007/s00223-022-01047-y, PubMed 36729139
Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy
J Thyroid Res, 2022, 8950546
DOI 10.1155/2022/8950546, PubMed 36248357
Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values
Bone, 162, 116478
DOI 10.1016/j.bone.2022.116478, PubMed 35779845
Target Values and Daytime Variation of Bone Turnover Markers in Monitoring Osteoporosis Treatment After Fractures
JBMR Plus, 6 (6), e10633
DOI 10.1002/jbm4.10633, PubMed 35720666
Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial
J Thyroid Res, 2022, 6423023
DOI 10.1155/2022/6423023, PubMed 35572853
Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study
Front Endocrinol (Lausanne), 13, 816566
DOI 10.3389/fendo.2022.816566, PubMed 35273566
Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis-The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint-A Review
Clin Pract, 11 (4), 901-913
DOI 10.3390/clinpract11040104, PubMed 34940003
Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial
J Bone Miner Res, 37 (1), 36-40
DOI 10.1002/jbmr.4457, PubMed 34633116
Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study
Front Endocrinol (Lausanne), 12, 785175
DOI 10.3389/fendo.2021.785175, PubMed 34867829
Evidence of impaired bone quality in men with type 1 diabetes: a cross-sectional study
Endocr Connect, 10 (8), 955-964
DOI 10.1530/EC-21-0193, PubMed 34289447
Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study
Obes Surg, 30 (9), 3426-3434
DOI 10.1007/s11695-020-04582-5, PubMed 32306297
Altered protein levels in bone marrow lesions of hip osteoarthritis: Analysis by proteomics and multiplex immunoassays
Int J Rheum Dis, 23 (6), 788-799
DOI 10.1111/1756-185X.13843, PubMed 32383346
Zoledronate
Bone, 137, 115390
DOI 10.1016/j.bone.2020.115390, PubMed 32353565
Bisphosphonates as a treatment modality in osteoarthritis
Bone, 143, 115352
DOI 10.1016/j.bone.2020.115352, PubMed 32247817
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
Bone, 134, 115296
DOI 10.1016/j.bone.2020.115296, PubMed 32097760
Post-fracture Risk Assessment: Target the Centrally Sited Fractures First! A Substudy of NoFRACT
J Bone Miner Res, 34 (11), 2036-2044
DOI 10.1002/jbmr.3827, PubMed 31310352
Changes in Bone Marrow Adipose Tissue One Year After Roux-en-Y Gastric Bypass: A Prospective Cohort Study
J Bone Miner Res, 34 (10), 1815-1823
DOI 10.1002/jbmr.3814, PubMed 31216081
Bone metabolism, bone mineral density and low-energy fractures 10 years after Roux-en-Y gastric bypass
Bone, 127, 436-445
DOI 10.1016/j.bone.2019.07.014, PubMed 31323430
Adding Marrow Adiposity and Cortical Porosity to Femoral Neck Areal Bone Mineral Density Improves the Discrimination of Women With Nonvertebral Fractures From Controls
J Bone Miner Res, 34 (8), 1451-1460
DOI 10.1002/jbmr.3721, PubMed 30883870
High prevalence of vertebral fractures and low trabecular bone score in patients with fragility fractures: A cross-sectional sub-study of NoFRACT
Bone, 122, 14-21
DOI 10.1016/j.bone.2019.02.008, PubMed 30743015
Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture Among Patients With a Fragility Fracture in the Norwegian Capture the Fracture Initiative (NoFRACT): A Trial Protocol
JAMA Netw Open, 1 (8), e185701
DOI 10.1001/jamanetworkopen.2018.5701, PubMed 30646281
Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques
J Bone Miner Res, 33 (12), 2230-2235
DOI 10.1002/jbmr.3565, PubMed 30102789
[Estrogens in menopause – time to change the guidelines?]
Tidsskr Nor Laegeforen, 138 (6)
DOI 10.4045/tidsskr.17.1059, PubMed 29557135
Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery
Clin Endocrinol (Oxf), 88 (3), 372-379
DOI 10.1111/cen.13531, PubMed 29235126
Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
Laryngoscope, 128 (3), 593-596
DOI 10.1002/lary.26722, PubMed 28671294
B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials
J Bone Miner Res, 32 (10), 1981-1989
DOI 10.1002/jbmr.3189, PubMed 28574605
Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial
Diabetes Care, 40 (7), 872-878
DOI 10.2337/dc16-2302, PubMed 28468770
Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy
PLoS One, 12 (4), e0175274
DOI 10.1371/journal.pone.0175274, PubMed 28419103
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial
BMC Neurol, 17 (1), 67
DOI 10.1186/s12883-017-0851-0, PubMed 28376767
Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study
Calcif Tissue Int, 101 (1), 34-42
DOI 10.1007/s00223-017-0256-5, PubMed 28246929
Women with type 2 diabetes mellitus have lower cortical porosity of the proximal femoral shaft using low-resolution CT than nondiabetic women, and increasing glucose is associated with reduced cortical porosity
Bone, 97, 252-260
DOI 10.1016/j.bone.2017.01.037, PubMed 28161589
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
BMC Neurol, 16 (1), 252
DOI 10.1186/s12883-016-0771-4, PubMed 27919248
Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality
Bone, 95, 41-46
DOI 10.1016/j.bone.2016.11.002, PubMed 27826025
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice
J Endocrinol, 230 (2), 251-62
DOI 10.1530/JOE-16-0017, PubMed 27325243
Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway
J Clin Endocrinol Metab, 101 (8), 3045-53
DOI 10.1210/jc.2016-1477, PubMed 27186861
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Bone, 86, 139-42
DOI 10.1016/j.bone.2016.02.009, PubMed 26944033
Determinants of Transitional Zone Area and Porosity of the Proximal Femur Quantified In Vivo in Postmenopausal Women
J Bone Miner Res, 31 (4), 758-66
DOI 10.1002/jbmr.2751, PubMed 26588794
Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years
J Bone Miner Res, 31 (2), 347-57
DOI 10.1002/jbmr.2696, PubMed 26308158
Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures
Bone, 81, 1-6
DOI 10.1016/j.bone.2015.06.016, PubMed 26112819
Single unit filter-aided method for fast proteomic analysis of tear fluid
Anal Biochem, 480, 1-5
DOI 10.1016/j.ab.2015.04.002, PubMed 25862084
High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study
Bone, 72, 65-70
DOI 10.1016/j.bone.2014.11.012, PubMed 25460573
Spinal deformities and lung function in adults with osteogenesis imperfecta
Clin Respir J, 8 (4), 437-43
DOI 10.1111/crj.12092, PubMed 24308436
Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes
PLoS One, 8 (12), e83983
DOI 10.1371/journal.pone.0083983, PubMed 24391858
Secondary hyperparathyroidism, vitamin D sufficiency, and serum calcium 5 years after gastric bypass and duodenal switch
Obes Surg, 23 (3), 384-90
DOI 10.1007/s11695-012-0772-3, PubMed 23015268
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
J Bone Miner Res, 28 (3), 442-8
DOI 10.1002/jbmr.1780, PubMed 23044788
Excessive decrease in serum magnesium after total thyroidectomy for Graves' disease is related to development of permanent hypocalcemia
World J Surg, 37 (2), 369-75
DOI 10.1007/s00268-012-1843-2, PubMed 23188529
Treatment of osteopenia
Rev Endocr Metab Disord, 13 (3), 209-23
DOI 10.1007/s11154-011-9187-z, PubMed 21710179
[When should bisphosphonate treatment be discontinued?]
Tidsskr Nor Laegeforen, 132 (14), 1630-2
DOI 10.4045/tidsskr.11.0788, PubMed 22875131
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective
J Bone Miner Res, 27 (5), 963-74
DOI 10.1002/jbmr.1570, PubMed 22467094
Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
PLoS One, 7 (9), e45703
DOI 10.1371/journal.pone.0045703, PubMed 23029191
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
BMC Endocr Disord, 11, 11
DOI 10.1186/1472-6823-11-11, PubMed 21615901
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
J Bone Miner Res, 26 (3), 503-11
DOI 10.1002/jbmr.238, PubMed 20814967
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
J Bone Miner Res, 26 (1), 12-8
DOI 10.1002/jbmr.180, PubMed 20645415
Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta
Arch Osteoporos, 6 (1), 31-8
DOI 10.1007/s11657-011-0054-z, PubMed 22207876
Cellular mechanisms of bone remodeling
Rev Endocr Metab Disord, 11 (4), 219-27
DOI 10.1007/s11154-010-9153-1, PubMed 21188536
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older
J Am Geriatr Soc, 58 (2), 292-9
DOI 10.1111/j.1532-5415.2009.02673.x, PubMed 20070415
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
J Bone Miner Res, 25 (1), 91-7
DOI 10.1359/jbmr.090704, PubMed 19580467
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis
J Bone Miner Res, 24 (9), 1544-51
DOI 10.1359/jbmr.090310, PubMed 19338427
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture
J Bone Miner Res, 24 (7), 1308-13
DOI 10.1359/jbmr.090209, PubMed 19257818
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Kidney Int, 74 (5), 641-8
DOI 10.1038/ki.2008.193, PubMed 18509324
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
J Bone Miner Res, 23 (1), 6-16
DOI 10.1359/jbmr.070906, PubMed 17892374
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial
J Am Dent Assoc, 139 (1), 32-40
DOI 10.14219/jada.archive.2008.0017, PubMed 18167382
Zoledronic acid and clinical fractures and mortality after hip fracture
N Engl J Med, 357 (18), 1799-809
DOI 10.1056/NEJMoa074941, PubMed 17878149
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
N Engl J Med, 356 (18), 1809-22
DOI 10.1056/NEJMoa067312, PubMed 17476007
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
J Bone Miner Res, 22 (1), 142-8
DOI 10.1359/jbmr.061001, PubMed 17032148
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
J Bone Miner Res, 21 (6), 855-64
DOI 10.1359/jbmr.060314, PubMed 16753016
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
Arch Intern Med, 165 (15), 1762-8
DOI 10.1001/archinte.165.15.1762, PubMed 16087825
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial
J Bone Miner Res, 20 (11), 1905-11
DOI 10.1359/JBMR.050714, PubMed 16234962
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women
Bone, 36 (6), 948-58
DOI 10.1016/j.bone.2005.03.003, PubMed 15878318
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial
J Clin Endocrinol Metab, 90 (8), 4644-9
DOI 10.1210/jc.2004-2489, PubMed 15914535
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study
J Bone Miner Res, 20 (9), 1548-61
DOI 10.1359/JBMR.050411, PubMed 16059627
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
J Clin Endocrinol Metab, 90 (7), 3970-7
DOI 10.1210/jc.2003-1703, PubMed 15840739
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
J Bone Miner Res, 20 (7), 1244-53
DOI 10.1359/JBMR.050309, PubMed 15940379
Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals
Toxicology, 199 (2-3), 129-36
DOI 10.1016/j.tox.2004.02.022, PubMed 15147787
Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma
Haematologica, 89 (5), 567-77
PubMed 15136220
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
J Bone Miner Res, 18 (11), 1932-41
DOI 10.1359/jbmr.2003.18.11.1932, PubMed 14606504
Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis
Bone, 32 (3), 297-310
DOI 10.1016/s8756-3282(02)00971-7, PubMed 12667558
A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells
J Bone Miner Res, 18 (2), 195-203
DOI 10.1359/jbmr.2003.18.2.195, PubMed 12568396
Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy
Br J Haematol, 120 (2), 235-42
DOI 10.1046/j.1365-2141.2003.04050.x, PubMed 12542480
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures
J Bone Miner Res, 17 (7), 1245-55
DOI 10.1359/jbmr.2002.17.7.1245, PubMed 12096838
Vitamin D deficiency and aging: implications for general health and osteoporosis
Biogerontology, 3 (1-2), 73-7
DOI 10.1023/a:1015263514765, PubMed 12014847
Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors
J Biol Chem, 277 (9), 7574-80
DOI 10.1074/jbc.M104608200, PubMed 11756404
Review articles
Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Bone, 120, 1-8
DOI 10.1016/j.bone.2018.09.020, PubMed 30268814
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Bone, 105, 11-17
DOI 10.1016/j.bone.2017.08.003, PubMed 28789921
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
J Bone Oncol, 7, 1-12
DOI 10.1016/j.jbo.2017.03.001, PubMed 28413771
Treatment of bone marrow lesions (bone marrow edema)
Bonekey Rep, 4, 755
DOI 10.1038/bonekey.2015.124, PubMed 26644910
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis
Bone, 67, 246-56
DOI 10.1016/j.bone.2014.07.014, PubMed 25053463
Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review
Bone, 58, 126-35
DOI 10.1016/j.bone.2013.09.023, PubMed 24120384
New developments in the treatment of osteoporosis
Acta Obstet Gynecol Scand, 92 (6), 620-36
DOI 10.1111/j.1600-0412.2012.01473.x, PubMed 22646526
[Denosumab for treatment of postmenopausal osteoporosis]
Tidsskr Nor Laegeforen, 131 (19), 1893-6
DOI 10.4045/tidsskr.10.1116, PubMed 21984295
Bone marrow lesions: a universal bone response to injury?
Rheumatol Int, 32 (3), 575-84
DOI 10.1007/s00296-011-2141-2, PubMed 21901347
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Bone, 42 (5), 841-7
DOI 10.1016/j.bone.2008.01.003, PubMed 18314405
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006
Crit Rev Oncol Hematol, 62 (2), 148-52
DOI 10.1016/j.critrevonc.2006.12.005, PubMed 17336086
Remodeling and vascular spaces in bone
J Bone Miner Res, 22 (1), 1-6
DOI 10.1359/jbmr.060910, PubMed 17040170
Teriparatide: A bone formation treatment for osteoporosis
Drugs Today (Barc), 40 (11), 935-48
DOI 10.1358/dot.2004.40.11.872582, PubMed 15645006
[D-vitamin: old paradoxes and new perspectives]
Ugeskr Laeger, 166 (1-2), 36-40
PubMed 14752991
Primary hyperparathyroidism: lessons from bone histomorphometry
J Bone Miner Res, 17 Suppl 2, N95-7
PubMed 12412784
Other articles
[Vitamin D and COVID-19 – can we draw any final conclusions?]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.22.0602, PubMed 36511736
[Bone turnover markers in the treatment of osteoporosis]
Tidsskr Nor Laegeforen, 141 (17)
DOI 10.4045/tidsskr.21.0119, PubMed 34813213
Leif Mosekilde IN MEMORIAM
J. Bone Miner. Res., 33 (11), 1913
DOI 10.1002/jbmr.3588
Oestrogens in menopause- time to change the recommendations?
Tidsskr. Nor. Laegeforen., 138 (6), 532-534
Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report
Bone Rep, 6, 81-86
DOI 10.1016/j.bonr.2017.02.006, PubMed 28377987
Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics"
Bone, 89, 75-76
DOI 10.1016/j.bone.2016.04.027, PubMed 27142587
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates]
Tidsskr Nor Laegeforen, 135 (10), 921
DOI 10.4045/tidsskr.15.0521, PubMed 26037748
Commentary on sclerostin deficiency is linked to altered bone composition
J Bone Miner Res, 29 (10), 2141-3
DOI 10.1002/jbmr.2346, PubMed 25158054
[Something to learn from--something to learn more from?]
Tidsskr Nor Laegeforen, 131 (22), 2221; author reply 2221
DOI 10.4045/tidsskr.11.0657, PubMed 22085940
[Osteonecrosis of the jaw]
Ugeskr Laeger, 171 (8), 629; author reply 629
PubMed 19291862